

|                              |               |  |              |
|------------------------------|---------------|--|--------------|
| <b>PHP_2.04.59</b>           |               | <b>Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies</b> |              |
| <b>Original Policy Date:</b> | March 1, 2026 | <b>Effective Date:</b>   | June 1, 2026 |
| <b>Section:</b>              | 2.0 Medicine  | <b>Page:</b>   | Page 1 of 34 |

**State Guidelines**

Applicable Medi-Cal guidelines as of the publication of this policy ([this guideline supersedes the criteria in the Policy Statement section below](#)):

- I. Department of Managed Health Care (DMHC) All Plan Letter (APL) Guideline:
  - N/A
  
- II. Department of Health Care Services (DHCS) Provider Manual Guideline:
  - [TAR and Non-Standard Benefits List: Codes 0001M thru 0999U \(tar and non cd0\)](#)
  - [TAR and Non-Standard Benefits List: Codes 80000 thru 89999 \(tar and non cd8\)](#)
  - [TAR and Non-Standard Benefits List: Codes R0000 thru S9999 \(tar and non cdrs\)](#)
  - [Pathology: Molecular Pathology \(path molec\)](#)

Below is an excerpt of the Molecular Pathology guideline language. Please refer to the specific Provider Manual in the link above for the complete guideline.

**Biomarker and Pharmacogenetic Testing**

Medi-Cal covers medically necessary biomarker and pharmacogenomic testing, as described in the manual section Proprietary Laboratory Analyses (PLA). Medi-Cal may not cover all CPT and HCPCS codes associated with a particular biomarker or pharmacogenomic test. As such, the particular biomarker or pharmacogenomic test code may be covered with an approved Treatment Authorization Request (TAR) if medical necessity is established, as described in the TAR and Non-Benefit: Introduction to List section of the Provider Manual.

**Biomarker Testing**

Biomarker testing is used to diagnose, treat, manage, or monitor a Medi-Cal member’s disease or condition to guide treatment decisions. As defined by Section 14132.09 of the Welfare and Institutions Code, biomarker testing is the analysis of an individual’s tissue, blood or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multiplex panel tests and whole genome sequencing. Biomarkers are a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention. A biomarker includes, but is not limited to, gene mutations or protein expression. Medically necessary biomarker testing is subject to utilization controls and evidence-based clinical practice guidelines.

When testing for biomarkers, all Medi-Cal providers must ensure that they are provided in a manner that limits disruptions to care. As with all Medi-Cal benefits, restricted or denied use of biomarker testing for the purpose of diagnosis, treatment or ongoing monitoring of any medical condition is subject to Medi-Cal’s grievance, appeal and State Fair Hearing processes, as well as any additional processes established specifically for Medi-Cal managed care plans.

**Requirements for CPT codes 81228 and 81229:**

A TAR requires documentation of all of the following criteria for each indication:

**For All Other Testing Indications:**

1. Member has received pre-test genetic counseling and will receive post-test genetic counseling, and
  2. Member's clinical phenotype does not fit a well-described syndrome for which single-gene or targeted panel testing is available, and
  3. One of the following criteria must be met (a thru e):
    - a. Intellectual disability or developmental delay with no identifiable cause, or
    - b. Multiple congenital anomalies without an established diagnosis, or
    - c. Autism spectrum disorder with no identifiable cause, or
    - d. Findings suggestive of primary immunodeficiency, or
    - e. Congenital heart disease
- III. Department of Health Care Services (DHCS) All Plan Letter (APL) Guideline:
- N/A

## Policy Statement

Any criteria that are not specifically addressed in the above Provider Manual, please refer to the criteria below.

- I. Chromosomal microarray analysis may be considered **medically necessary** as first-line testing in the initial evaluation (see Policy Guidelines) of individuals with **any** of the following:
  - A. Apparent nonsyndromic developmental delay/intellectual disability
  - B. Autism spectrum disorder
  - C. Multiple congenital anomalies not specific to a well-delineated genetic syndrome  
*(Per Medi-Cal guidelines and for Medi-Cal members only, the following must also be met:*
    1. *Member must have received pre-test genetic counseling and will receive post-test genetic counseling*
    2. *Member's clinical phenotype does not fit a well-described syndrome for which single-gene or targeted panel testing is available)*
- II. Chromosomal microarray is considered **investigational** for the evaluation of all other conditions of delayed development, including, but not limited to, idiopathic growth or language delay.
- III. Panel testing using next-generation sequencing is considered **investigational** in all cases of suspected genetic abnormality in children with developmental delay/intellectual disability, autism spectrum disorder, or congenital anomalies.

## Policy Guidelines

Use of chromosomal microarray (CMA) testing as outlined in this policy is not intended for use in the prenatal period.

A guideline update from the American College of Medical Genetics (Schaefer et al [2013]) stated that a stepwise (or tiered) approach to the clinical genetic diagnostic evaluation of autism spectrum disorder is recommended, with the recommendation being for first tier to include fragile X syndrome and CMA testing.

Recommendations from the American College of Medical Genetics (Manning and Hudgins [2010]) on array-based technologies and their clinical utilization for detecting chromosomal abnormalities include the following: "Appropriate follow-up is recommended in cases of chromosome imbalance identified by CMA, to include cytogenetic/FISH [fluorescent in situ hybridization] studies of the patient, parental evaluation, and clinical genetic evaluation and counseling."

In some cases of CMA analysis, the laboratory performing the test confirms all reported copy number variants with an alternative technology, such as fluorescent in situ hybridization analysis.

### Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology - "pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign" - to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

| Previous | Updated                    | Definition  |
|----------|----------------------------|---|
| Mutation | Disease-associated variant | Disease-associated change in the DNA sequence   |
|          | Variant                    | Change in the DNA sequence  |
|          | Familial variant           | Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives |

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

| Variant Classification            | Definition   |
|-----------------------------------|--|
| Pathogenic                        | Disease-causing change in the DNA sequence               |
| Likely pathogenic                 | Likely disease-causing change in the DNA sequence        |
| Variant of uncertain significance | Change in DNA sequence with uncertain effects on disease |
| Likely benign                     | Likely benign change in the DNA sequence                 |
| Benign                            | Benign change in the DNA sequence                        |

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

### Coding

See the [Codes table](#) for details.

## Description

Chromosomal microarray (CMA) testing has been proposed for the detection of genetic imbalances in infants or children with characteristics of developmental delay/intellectual disability, autism spectrum disorder, and/or congenital anomalies. CMA testing increases the diagnostic yield over karyotyping in children with the aforementioned characteristics, and CMA testing may impact clinical management decisions. Next-generation sequencing panel testing allows for the simultaneous analysis of a large number of genes and, in patients with normal CMA testing, next-generation testing has been proposed as a way to identify single-gene causes of syndromes that have autism as a significant clinical feature.

### Summary of Evidence

For individuals who have developmental delay/intellectual disability, autism spectrum disorder (ASD), or multiple congenital anomalies not specific to a well-delineated genetic syndrome who receive chromosomal microarray (CMA) testing, the evidence includes primarily case series. Relevant outcomes are test validity, changes in reproductive decision making, morbid events, and resource utilization. The available evidence supports test validity. Although systematic studies of the impact of CMA on patient outcomes are lacking, the improvement in diagnostic yield over karyotyping has been well-demonstrated. Direct evidence of improved outcomes with CMA compared with karyotyping is also lacking. However, for at least a subset of the disorders potentially diagnosed with CMA testing in this patient population, there are well-defined and accepted management steps associated with positive test results. Further, there is evidence of changes in reproductive decision-making as a result of positive test results. The information derived from CMA testing can accomplish the following: it could end a long diagnostic odyssey, reduce morbidity for certain conditions by initiating surveillance/management of associated comorbidities, or it could impact future reproductive decision making for parents. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have developmental delay/intellectual disability, ASD, or multiple congenital anomalies not specific to a well-delineated genetic syndrome who receive next-generation sequencing panel testing, the evidence includes primarily case series and 1 systematic review. Relevant outcomes are test validity, changes in reproductive decision-making, morbid events, and resource utilization. The diagnostic yield associated with next-generation sequencing panel testing in this patient population is not well-characterized. The testing yield and likelihood of an uncertain result are variable, based on the gene panel, gene tested, and patient population; additionally, there are risks of uninterpretable and incidental results. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Additional Information

Not applicable.

## Related Policies

- N/A

## Benefit Application

Blue Shield of California Promise Health Plan is contracted with L.A. Care Health Plan for Los Angeles County and the Department of Health Care Services for San Diego County to provide Medi-Cal health benefits to its Medi-Cal recipients. In order to provide the best health care services and

practices, Blue Shield of California Promise Health Plan has an extensive network of Medi-Cal primary care providers and specialists. Recognizing the rich diversity of its membership, our providers are given training and educational materials to assist in understanding the health needs of their patients as it could be affected by a member's cultural heritage.

The benefit designs associated with the Blue Shield of California Promise Medi-Cal plans are described in the Member Handbook (also called Evidence of Coverage).

## Regulatory Status

### **Cal. Health & Safety Code §1367.667, Insurance Code Section 10123.209, and Welfare and Institutions Code 14132.09**

California laws that require insurers to cover biomarker testing for the diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition to guide treatment decisions, as prescribed

### **Clinical Laboratory Improvement Amendments (CLIA) and FDA Regulatory Overview**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Lab tests for CMA testing and next-generation sequencing are available under the auspices of Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

In 2010, the FDA indicated that it would require microarray manufacturers to seek clearance to sell their products for use in clinical cytogenetics.

### **Chromosomal Microarray Testing**

CMA testing is commercially available through many laboratories and includes targeted and whole-genome arrays, with or without SNV microarray analysis.

In January 2014, the Affymetrix CytoScan® Dx Assay (now Thermo Fisher Scientific) was cleared by the FDA through the de novo 510(k) process. The FDA's review of the CytoScan Dx Assay included an analytic evaluation of the test's ability to detect accurately numerous chromosomal variations of different types, sizes, and genome locations compared with several analytically validated test methods. The FDA found that the CytoScan Dx Assay could detect CNVs across the genome and adequately detect CNVs in regions of the genome associated with developmental delay/intellectual disability. Reproducibility decreased with the CNV gain or loss size, particularly when less than approximately 400 kilobases (generally recommended as the lower reporting limit). As of September 2024, CytoScan HD Array contains 2.67 million markers for copy number, 750,000 SNVs, and 1.9 million non-polymorphic probes. FDA product code: PFX.

Ambry Genetics offers multiple tests (CMA and next-generation sequencing) designed for diagnosing ASD and neurodevelopmental disorders. As of September 2024, the CMA offered by Ambry Genetics includes over 1.9 million probes for copy number and ~750,000 SNV probes.

LabCorp offers the Reveal® SNP Microarray Pediatric for individuals with nonsyndromic congenital anomalies, dysmorphic features, developmental delay/intellectual disability, and/or ASD. The Reveal microarray has over 2 million probes.

### Next-Generation Sequencing

A variety of commercial and academic laboratories offer next-generation sequencing panels designed for the evaluation of ASD, developmental delay/intellectual disability, and congenital anomalies, which vary in terms of the numbers of, and specific genes tested.

Emory Genetics Laboratory offers a next-generation sequencing ASD panel of genes targeting genetic syndromes that include autism or autistic features. Fulgent Genetics offers a next-generation sequencing ASD panel that includes hundreds of genes. Ambry Genetics also offers numerous next-generation sequencing panels for neurodevelopmental disorders.

## Health Equity Statement

Blue Shield of California Promise Health Plan's mission is to transform its health care delivery system into one that is worthy of families and friends. Blue Shield of California Promise Health Plan seeks to advance health equity in support of achieving Blue Shield of California Promise Health Plan's mission.

Blue Shield of California Promise Health Plan ensures all Covered Services are available and accessible to all members regardless of sex, race, color, religion, ancestry, national origin, ethnic group identification, age, mental disability, physical disability, medical condition, genetic information, marital status, gender, gender identity, or sexual orientation, or identification with any other persons or groups defined in Penal Code section 422.56, and that all Covered Services are provided in a culturally and linguistically appropriate manner.

## Rationale

### Background Diagnostic Testing

#### Karyotyping and Fluorescent In Situ Hybridization

The goal of a cytogenetic evaluation is to identify chromosomal imbalances that cause a disorder. The most common imbalances are copy number variants (CNVs) or deletions and duplications of large segments of genomic material. CNVs are common in developmental delay/intellectual disability and autism spectrum disorder (ASD) but more often reflect the normal genetic variation.<sup>1</sup> However, de novo CNVs are observed about 4 times more frequently in children with ASD than in individuals without ASD.<sup>2</sup> Less frequently, other abnormalities such as balanced translocations (i.e., exchanges of equally sized DNA loci between chromosomes) may be pathogenic. For many well-described syndromes, the type and location of the associated chromosomal abnormality have been established by studying large patient samples. For others, few patients with similar abnormalities may have been evaluated to establish genotype-phenotype correlation. Finally, in some patients, the cytogenetic analysis will discover chromosomal abnormalities that require study to determine their significance.

Prior to the advent of chromosomal microarray (CMAs), the initial step in the cytogenetic analysis was G-banded karyotyping, which evaluates all chromosomes. High-resolution G-banding can detect changes as small as 3 to 5 megabases in size, although standard G-banding evaluates more than 10 megabases changes. In children with developmental delay/intellectual disability, a review by Stankiewicz and Beaudet (2007) found G-banded karyotyping diagnostic in approximately 3% to 5% of cases.<sup>3</sup> In ASD, high-resolution karyotyping appears to identify abnormalities in up to 5% of cases.<sup>4</sup>

In contrast, molecular cytogenetic techniques can detect small submicroscopic chromosomal alterations. Fluorescent in situ hybridization (FISH), a targeted approach, is used to identify specific

chromosomal abnormalities associated with suspected diagnoses such as DiGeorges syndrome. Prior to CMAs, FISH was also used to screen the rearrangement-prone sub-telomeric regions. Subtelomeric FISH was found to identify abnormalities in children with developmental delay and intellectual disability,<sup>5</sup> and was diagnostic in approximately 5% to 6% of those with negative karyotypes, but uncommonly in ASD.<sup>6</sup>

### Chromosomal Microarrays

Two types of CMAs are considered here: array comparative genomic hybridization (aCGH) and single nucleotide variants (SNV) arrays. The aCGH approach uses DNA samples from a patient and normal control. Each is labeled with distinct fluorescent dyes (red or green). The labeled samples are then mixed and hybridized to thousands of cloned or synthesized reference (normal) DNA fragments of known genomic locus immobilized on a glass slide (microarray) to conduct thousands of comparative reactions simultaneously. CNVs are determined by computer analysis of the array patterns and intensities of the hybridization signals. If the patient sequence is missing part of the normal sequence (a deletion) or has the normal sequence plus additional genomic material within that genomic location (e.g., a duplication), the sequence imbalance is detected as a difference in fluorescence intensity (Korf and Rehm [2013]<sup>7</sup> offers an illustrative graphic). For this reason, aCGH cannot detect balanced chromosomal translocations (equal exchange of material between chromosomes) or sequence inversions (same sequence is present in reverse base-pair order) because the fluorescence intensity would not change. A portion of the increased diagnostic yield from CMA over karyotyping comes from the discovery that chromosomal rearrangements that appear balanced (and therefore not pathogenic) by G-banded karyotype analysis are found to have small imbalances with greater resolution. It has been estimated that 40% of apparently balanced de novo or inherited translocations with abnormal phenotype are associated with cryptic deletion if analyzed by CMA testing.

Like aCGH, SNV arrays detect CNVs. In an SNV array, the 2 alleles for genes of interest are tagged with different fluorescent dyes. Comparative fluorescence intensity will be increased when there are duplications and diminished with deletions. The resolution provided by aCGH is higher than with SNV arrays. In addition, aCGH has better signal-to-background characteristics than SNV arrays. In contrast to aCGH, SNV arrays will also identify long stretches of DNA homozygosity, which may suggest uniparental disomy or consanguinity. Uniparental disomy occurs when a child inherits 2 copies of a chromosome from 1 parent and no copies from the other parent. Uniparental disomy can lead to syndromes such as Angelman and Prader-Willi.

Table 1 summarizes the cytogenetic tests used to evaluate children with developmental delay/intellectual disability and autism. The table emphasizes the large difference in resolution between karyotyping and CMA.

**Table 1. Resolution and Analysis Comparison of FISH, Karyotyping, and CMA Analysis**

| Test        | Resolution in Kilobases <sup>a</sup> | Analysis    |
|-------------|--------------------------------------|-------------|
| Karyotyping | 3000-5000 kb                         | Genome-wide |
| CMA         | ≈50 kb                               | Genome-wide |
| FISH        | ≈500 to 1000 kb (depending on probe) | Targeted    |

CMA: chromosomal microarray; FISH: fluorescent in situ hybridization; kb: kilobases.

<sup>a</sup>1 kb = 1000 bases, 1000 kb = 1 Mb.

Microarrays may be prepared by the laboratory using the technology or, more commonly, by commercial manufacturers, and sold to laboratories that must qualify and validate the product for use in their assay, in conjunction with computerized software for interpretation. The proliferation of laboratory-developed and commercially available platforms prompted the American College of Medical Genetics to publish guidelines for the design and performance expectations for clinical microarrays and associated software in the postnatal setting.<sup>8</sup>

### **Next-Generation Sequencing**

Next-generation sequencing has been proposed to detect single-gene causes of autism and possibly identify a syndrome that involves autism in patients with normal array-based testing. Next-generation sequencing involves the sequencing of millions of fragments of genetic material in a massively parallel fashion. Next-generation sequencing can be performed on segments of the genetic material of various sizes from the entire genome (whole-genome sequencing) to small subsets of genes (targeted sequencing). Next-generation sequencing allows the detection of SNVs, CNVs, insertions, and deletions. With higher resolution comes a higher likelihood of detection of variants of uncertain significance.

### **Genetic Associations With Developmental Delay/Intellectual Disability and Autism Spectrum Disorder**

For common phenotypes and syndromes, the pathogenicity of CNVs may be supported by considerable evidence; for uncommon phenotypes and uncommon CNVs determining pathogenicity requires a systematic evaluation that includes parental studies, examining databases for reported associations, and considering the molecular consequences of the identified variant. Parental studies (e.g., “trio” testing of affected child, father, and mother) can identify an inherited CNV from an unaffected parent and therefore considered benign.<sup>9</sup> A variety of databases index the clinical implications of CNVs and their associations with a particular phenotype. CNVs are continuously cataloged and, with growth in CMA testing and improved resolution, databases have become increasingly extensive (e.g., DECIPHER, ClinVar). For uncommon CNVs, in addition to reports of CNV-phenotype associations, the location and size of the CNV can offer clues to pathogenicity; larger CNVs are more often pathogenic and the role of affected genes in brain circuitry and the effect of CNV on gene expression can implicate pathogenicity. Although uncommon, an observed phenotype can result from unmasking a mutated recessive allele on the unaffected (non-CNV) chromosome.<sup>10</sup> Other considerations when determining pathogenicity include CNV dosage, X linkage, number of reports in the literature of an association between CNV and phenotype, and findings in “normal” individuals.

The American College of Medical Genetics has published guidelines for evaluating, interpreting, and reporting pathogenicity reflecting these principles.<sup>11</sup> The recommended categories of clinical significance for reporting are pathogenic, uncertain clinical significance (likely pathogenic, likely benign, or no subclassification), or benign. The International Standards for Cytogenomic Arrays Consortium more recently proposed “an evidence-based approach to guide the development of content on chromosomal microarrays and to support the interpretation of clinically significant copy number variation.”<sup>12</sup> The proposal defined levels of evidence that describe how well or how poorly detected variants or CNVs correlate with phenotype.

### **Literature Review**

This review has been informed by a Technology Evaluation Center (TEC) Special Report (2009) on array comparative genomic hybridization (aCGH)<sup>13</sup> and a TEC Special Report (2015) on chromosomal microarray (CMA) testing for the genetic evaluation of individuals with global developmental delay, intellectual disability, and autism spectrum disorder (ASD).<sup>14</sup>

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical

reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

### **Developmental Delay/Intellectual Disability**

Developmental delay is diagnosed in children 5 years or younger who show a significant delay in 2 or more developmental domains: gross or fine motor, speech/language, cognitive, social/personal, and activities of daily living.<sup>15</sup> Developmental delay can precede the development of intellectual disability as the child ages.<sup>16</sup>

Intellectual disability is manifest by significant limitations in intellectual functioning and adaptive behavior. It is diagnosed at or after age 5 (when intelligence testing is considered valid and reliable) but prior to age 18 and is lifelong. The *Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition (DSM-5)* defines intellectual disability as occurring during the developmental period and involving impairments of general mental abilities (e.g., IQ <70 or 75) that impact adaptive functioning in the conceptual, social, and practical domains.<sup>17</sup>

The national prevalence of developmental delay and intellectual disability were estimated at 4.1% and 1.2%, respectively, in US children based on data from the 2009 to 2017 National Health Interview Survey, and overall developmental disability was reported to be 8.56% in 2021.<sup>18,19</sup> All are influenced by genetic, environmental, infectious, and perinatal factors. Approximately 450 genes have been causally related to intellectual disability; most genes (>90%) are associated with syndromes.<sup>20</sup> Inheritance of intellectual disability can be autosomal-dominant, recessive, or X-linked; and most nonsyndromic genes are located on the X chromosome. Prior to the advent of whole-exome and genome sequencing, Willemsen and Kleefstra (2014) concluded that 20% to 40% of intellectual disability cases could be attributed to a genetic variant.<sup>21</sup> With the use of whole-genome sequencing, they estimated almost 60% of cases have an identifiable genetic etiology.

Congenital anomalies are frequently present in children with developmental delay and intellectual disability. In addition, a suspected etiology can often be established from history and physical examination (for skilled specialists, as much as 20% to 40% of cases) without genetic testing.<sup>22</sup> The recommended approach to evaluation in developmental delay/intellectual disability begins with 3-generation family history and physical (including neurologic) exam. Subsequent testing is used to confirm a suspected diagnosis (e.g., targeted fluorescent in situ hybridization [FISH] testing for DiGeorge or cri-du-chat syndromes). If no diagnosis is suspected, fragile X syndrome testing, metabolic testing for inborn errors of metabolism, and CMA testing (without karyotyping) are recommended, regardless of the presence or absence of dysmorphic features or congenital anomalies.<sup>15</sup>

### **Autism Spectrum Disorder**

*DSM-5* defines ASD<sup>15</sup> as the presence of<sup>17</sup>:

- Persistent deficits in social communication and social interaction across multiple contexts,
- Restricted, repetitive patterns of behavior, interests, or activities,
- Symptoms in the early developmental period (typically recognized in the first 2 years of life), and
- Symptoms causing clinically significant impairment in social, occupational, or other important areas of current functioning.

The estimated prevalence of ASD in U.S. children is estimated to be 3.11%, and is higher among boys (4.66%) than girls (1.50%).<sup>19</sup> Prevalence is highest among Black, non-Hispanic individuals (3.56%) followed by White, non-Hispanic (3.06%) individuals, Hispanic (2.96%) individuals, and Asian, non-Hispanic individuals (2.87%). An accurate diagnosis can generally be made by age 2. The evaluation

includes developmental screening and diagnostic evaluation (i.e., hearing, vision, and neurologic testing; laboratory testing for metabolic disorders; and genetic testing).

A large body of evidence supports a genetic etiology in ASD. Twin studies estimate heritability between 60% and 90%.<sup>2</sup> A family with an affected child has a 13% to 19% risk for recurrence in subsequent children.<sup>23</sup> Based on Swedish genetic studies, Gaugler et al (2014) concluded that “the bulk of autism arises from genetic variation” (as opposed to environmental causes).<sup>24</sup> Still, although genetic determinants can be heritable, most appear to arise de novo.<sup>2</sup>

For these reasons, a child with ASD is often evaluated with genetic testing. Testing may be targeted when a child has a recognizable syndrome such as those shown in Table 2. Alternatively, high-resolution cytogenetic analysis evaluating multiple genes, the focus of this evidence review, is used.

**Table 2. Examples of Specific Genes Associated With Disorders That Include Autistic Behaviors**

| Gene (Syndrome)         | Patient Selection   | Yield, % | Reference                                    |
|-------------------------|---|----------|--|
| <i>FMR1</i> (fragile X) | Unselected autism   | 3-10     | Schaefer and Mendelsohn (2008) <sup>25</sup> |
| <i>MECP2</i> (Rett)     | Females with nonsyndromic autism, intellectual disability, and cerebral palsy | 3-13     |  |
| <i>PTEN</i>             | Autism with macrocephaly  | ≤17      | Butler et al (2005) <sup>26</sup>            |

### Chromosomal Microarray Testing

#### Clinical Context and Test Purpose

The purpose of CMA testing is to identify a genetic cause for individuals with developmental delay/intellectual disability, ASD, and congenital anomalies. A genetic diagnosis may end a diagnostic odyssey, improve treatment, facilitate the management of associated medical conditions, and permit carrier testing to assess risks to future offspring.

The following PICO was used to select literature to inform this review.

#### Populations

The relevant population of interest is children with developmental delay/intellectual disability, ASD, and congenital anomalies for whom the cause of the disorder has not been identified despite other established methods such as karyotyping.

#### Interventions

The relevant intervention of interest is CMA testing. Referral for genetic counseling is important for the explanation of the genetic disease, heritability, genetic risk, test performance, and possible outcomes.

#### Comparators

The following practice is currently being used to diagnose developmental delay/intellectual disability, ASD, and congenital anomalies: karyotyping. Referral for genetic counseling is important for the explanation of the genetic disease, heritability, genetic risk, test performance, and possible outcomes.

#### Outcomes

The potential beneficial outcomes of interest are diagnostic yield with avoidance of future testing, changes in management that lead to an improvement in health outcomes, and identification of unaffected carriers.

Potential harmful outcomes are those resulting from a false-positive or false-negative test result. False-positive test results can lead to an incorrect diagnosis and inappropriate treatment. False-

negative test results can lead to the absence of appropriate treatment and continuation of the diagnostic odyssey.

Follow-up to monitor for outcomes varies from immediately after testing diagnosis to long-term health outcomes subsequent to management changes.

### Study Selection Criteria

For the evaluation of clinical validity of the CMA test, studies that met the following eligibility criteria were considered:

- case series or cohort studies that enrolled 20 or more patients with clinical diagnoses of developmental delay/intellectual disability or ASD with known or suspicion of genetic abnormalities, with or without negative results by conventional cytogenetic evaluation, and performed CMA testing on enrolled patients, or
- examined management decisions and/or patient outcomes based on genetic evaluation results.

### Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### Case Series or Cohort Studies

Several studies have conducted CMA testing on samples with known chromosomal abnormalities using standard karyotyping, which are summarized in Table 3. The median diagnostic yield in developmental delay/intellectual disability patients from 21 studies published after 2012 was 19%. Most studies included patients with prior normal studies (e.g., karyotype and *FMR1* testing). However, it is difficult to assess phenotype severity across studies owing to reporting and how samples were assembled. For a recent comparison, investigators reported diagnostic yield from 1133 children enrolled in the U.K. Deciphering Developmental Disorders study for whom a diagnosis was not established prior to CMA testing.<sup>27</sup> Using both CMA and exome sequencing, a diagnostic yield of 27% was achieved.

**Table 3. Diagnostic Yield of 67 Case Series Assessing Chromosomal Microarray Testing for Developmental Delay, Intellectual Disability, and ASD Published Before 2015**

| Study                               | N   | Diagnoses    | Patient Description   | Previous Normal Studies  | Yield, % |
|-------------------------------------|-----|--------------|---|--|----------|
| Eriksson et al (2015) <sup>28</sup> | 162 | ASD          | Suspected ASD   | Karyotype (unclear precise proportion but < half)  | 8.6      |
| Lay-Son et al (2015) <sup>29</sup>  | 40  | DD/ID/other  | Patients had at least 2 of the following: CAs, facial dysmorphism, DD/ID                          | Karyotype, 4 (10%) patients had an abnormality on karyotype but it did not convey a definite cause of patients' disorder | 25       |
| Bartnik et al (2014a) <sup>30</sup> | 256 | DD/ID        | DD/ID with or without dysmorphic features, additional neurodevelopmental abnormalities, and/or CA | G-banded karyotype, fragile X testing  | 27       |
| Bartnik et al (2014b) <sup>31</sup> | 112 | DD/ID        | ID accompanied by dysmorphic features and/or CA   | G-banded karyotype, fragile X testing, MPLA  | 21.4     |
| Chong et al (2014) <sup>32</sup>    | 115 | DD/ID/ASD/CA | 105 patients with DD/ID/ASD/CA recruited by clinical genetics services                            | Karyotype  | 19       |

| Study                                    | N    | Diagnoses | Patient Description   | Previous Normal Studies   | Yield, % |
|--|------|-----------|---|---|----------|
| D'Amours et al (2014) <sup>33</sup>      | 21   | CA        | DD/ID with or without CA  | Karyotype   | 14.3     |
| Henderson et al (2014) <sup>34</sup>     | 1780 | DD/ID/ASD | Referral to a laboratory for CMA  | Not specified   | 12.7     |
| Nava et al (2014) <sup>35</sup>          | 194  | ASD       | ASD   | Karyotype, fragile X testing, FISH                                    | 1.5      |
| Nicholl et al (2014) <sup>36</sup>       | 1700 | DD/ID/ASD | 1453 unrelated patients prospectively referred for investigation of DD/ID/ASD and 247 epilepsy cases  | Uncertain   | 11.5     |
| Palmer et al (2014) <sup>37</sup>        | 67   | ID        | Idiopathic ID   | Karyotype, fragile X, 19 subtelomeric MPLA                            | 19       |
| Preiksaitiene et al (2014) <sup>38</sup> | 211  | DD/ID     | Syndromic and nonsyndromic cases of unknown etiology of DD/ID   | FISH, MLPA, or karyotype  | 13.7     |
| Redin et al (2014) <sup>39</sup>         | 106  | DD/ID     | Idiopathic ID   | Karyotype   | 24.5     |
| Roberts et al (2014) <sup>40</sup>       | 215  | DD/ID/ASD | ID/ASD  | Uncertain   | 14.9     |
| Stobbe et al (2014) <sup>41</sup>        | 23   | ASD       | Retrospective review of patients referred for autism testing  | Karyotype (<44%patient, 1 patient with known chromosomal abnormality) | 21.7     |
| Tao et al (2014) <sup>42</sup>           | 327  | DD/ID/ASD | Patients seen by a clinical geneticist  | Not specified   | 11.3     |
| Utine et al (2014) <sup>43</sup>         | 100  | ID        | Idiopathic ID   | Karyotype, FISH   | 12       |
| Uwineza et al (2014) <sup>44</sup>       | 50   | DD/ID     | DD/ID/MCA   | Karyotype   | 26       |
| Battaglia et al (2013) <sup>45</sup>     | 349  | DD/ID/ASD | Idiopathic DD/ID/ASD or dysmorphism   | FISH or karyotype   | 22.1     |
| Lee et al (2013) <sup>46</sup>           | 190  | DD/ID     | Retrospective chart review of patients at single-center with idiopathic DD/ID   | G-banded karyotype  | 13.7     |
| Shoukier et al (2013) <sup>47</sup>      | 342  | DD/ID     | Retrospective review of idiopathic DD/ID  | Karyotype   | 13.2     |
| Sorte et al (2013) <sup>48</sup>         | 50   | ASD       | ASD   | G-banded karyotype  | 16       |
| Filges et al (2012) <sup>49</sup>        | 131  | DD/ID/ASD | Consecutive patients with normal karyotype but presenting with chromosomal phenotypes: malformation syndromes, syndromic and nonsyndromic ID, and ASD | Karyotype   | 25.2     |
| Iourov et al (2012) <sup>50</sup>        | 54   | ID/ASD/CA | Highly selected patients from a group of 2426 patients based on clinical and cytogenetic data   | G-banded karyotype  | 28       |
| McGrew et al (2012) <sup>51</sup>        | 97   | ASD       | Retrospective review of EMR for patients with ASD or pervasive DD NOS   | Uncertain (karyotype?)  | 6.2      |
| Tzetzis et al (2012) <sup>52</sup>       | 334  | DD/ID/ASD | DD/ID/ASD or with major CA or dysmorphic features   | Karyotype, FISH, fragile X and Rett syndromes                         | 25.1     |
| Bremer et al (2011) <sup>53</sup>        | 223  | ASD       | 151 diagnosed ASD with normal karyotype, 1 nonpathogenic inherited balanced translocation, 72 patients who had not received karyotyping               | Karyotype   | 8.1      |
| Coulter et al (2011) <sup>54</sup>       | 1792 | DD/ID/ASD | DD/ID/ASD, CA, dysmorphic features, seizures, hypotonia   | "Majority" karyotype  | 7.3      |

| Study                                | N    | Diagnoses | Patient Description   | Previous Normal Studies  | Yield, % |
|--------------------------------------|------|-----------|---|--|----------|
| Wincent et al (2011) <sup>55</sup>   | 160  | DD/CA     | Idiopathic DD/CA  | Karyotype, fragile X, 13.1 FISH, MPLA                                      |          |
| Manolakos et al (2010) <sup>56</sup> | 82   | ID        | Idiopathic MR   | G-banded karyotype   | 3.6      |
| Rosenfeld et al (2010) <sup>57</sup> | 1461 | ASD       | Retrospective review of putative ASD submitted for clinical testing                                   | Not specified  | 7.7      |
| Schaefer et al (2010) <sup>58</sup>  | 68   | ASD       | Retrospective review of patients who had received aCGH for autism                                     | Uncertain  | 22       |
| Shen et al (2010) <sup>59</sup>      | 848  | ASD       | Idiopathic MR and/or dysmorphism or MCAs  | G-banded karyotype, fragile X  | 7        |
| Bruno et al (2009) <sup>60</sup>     | 117  | DD/ID     | Idiopathic MR and/or CA   | Karyotype (400 to 650-band level)  | 15.4     |
| Friedman et al (2009) <sup>61</sup>  | 100  | ID        | Moderate-to-severe idiopathic DD/MR with CA   | Uncertain  | 16       |
| Baldwin et al (2008) <sup>62</sup>   | 211  | DD/ID/ASD | Various, including idiopathic DD/ID, dysmorphic features, CA, ASD, or syndromal phenotype             | G-banded karyotype ("many")  | 15.6     |
| Christian et al (2008) <sup>63</sup> | 397  | ASD       | Nonsyndromic autism, subset of AGRE subjects (Roswell Park Cancer Institute)                          | Karyotype  | 11.6     |
| Marshall et al (2008) <sup>64</sup>  | 427  | ASD       | ASD   | Karyotype (32 with known abnormality)                                      | 6.3      |
| Pickering et al (2008) <sup>65</sup> | 1176 | DD/ID/CA  | Consecutive cases referred for idiopathic DD/MR/MCA or other dysmorphism                              | Karyotype (30 with visible chromosomal abnormality), FISH in some patients | 9.8      |
| Saam et al (2008) <sup>66</sup>      | 490  | DD/ID     | DD/ID   | Karyotype  | 17.6     |
| Shevell et al (2008) <sup>67</sup>   | 94   | DD/ID     | DD  | G-banded karyotype, fragile X, <i>FMR1</i> , neuroimaging                  | 6.4      |
| Aradhya et al (2007a) <sup>68</sup>  | 20   | DD/ID     | DD/ID and either dysmorphic features, CA, or growth retardation                                       | G-banded karyotype, FISH   | 30       |
| Aradhya et al (2007b) <sup>68</sup>  | 20   | DD/ID     | As above  | As above   | 50       |
| Ballif et al (2007) <sup>69</sup>    | 6946 | DD/ID     | Various clinical presentations, most commonly DD, dysmorphic features, and/or MCA                     | Karyotype, subtelomere FISH  | 2.4      |
| Froyen et al (2007) <sup>70</sup>    | 108  | DD/ID     | Suspicious for X-linked MR  | G-banded karyotype, <i>FMR1</i>  | 13       |
| Hoyer et al (2007) <sup>71</sup>     | 104  | DD/ID     | Unselected patients with idiopathic MR  | G-banded karyotype   | 9.1      |
| Lu et al (2007) <sup>72</sup>        | 1726 | DD/ID     | DD/ID, dysmorphic, or MCA features  | G-banded karyotype and/or FISH   | 5.2      |
| Madrigal et al (2007) <sup>73</sup>  | 54   | DD/ID     | Idiopathic MR; 52 from families with X-linked inherited MR; 2 with suspicion of X chromosome deletion | Karyotype, <i>FMR1</i>   | 11.6     |
| Sebat et al (2007) <sup>74</sup>     | 195  | ASD       | Nonsyndromic autism; majority from AGRE or NIMH Center for  | Karyotype  | 7.2      |

| Study   | N    | Diagnoses | Patient Description   | Previous Normal Studies                                   | Yield, % |
|---|------|-----------|---|---|----------|
| Collaborative Genetic Studies on Mental Disorders |      |           |   |   |          |
| Shen et al (2007) <sup>75</sup>                   | 211  | DD/ID     | ASD   | Not selected by prior results                             | 8.1      |
| Thuresson et al (2007) <sup>76</sup>              | 48   | DD/ID     | Idiopathic MR and CA  | G-banded karyotype, subtelomere FISH                      | 6        |
| Wagenstaller et al (2007) <sup>77</sup>           | 67   | DD/ID     | Idiopathic MR   | G-banded karyotype, FISH (n=42)                           | 16.4     |
| Ballif et al (2006) <sup>78</sup>                 | 3600 | DD/ID     | Consecutive cases with diverse range of DD or MR features   | Not specified   | 5.1      |
| Friedman et al (2006) <sup>79</sup>               | 100  | DD/ID     | Idiopathic ID   | Karyotype   | 11       |
| Jacquemont et al (2006) <sup>80</sup>             | 29   | ASD       | Syndromic ASD   | Karyotype, biochemical tests                              | 28       |
| Krepischi-Santos et al (2006) <sup>29</sup>       | 95   | DD/ID     | Syndromic MR or other   | G-banded karyotype, <i>FMR1</i> (in some)                 | 15.8     |
| Lugtenberg et al (2006) <sup>81</sup>             | 40   | DD/ID     | Idiopathic MR, suspicious for X-linked abnormality  | Karyotype   | 7.5      |
| Menten et al (2006) <sup>82</sup>                 | 140  | DD/ID     | Idiopathic MR and MCA   | Karyotype, subtelomere MPLA (n=31)                        | 13.6     |
| Miyake et al (2006) <sup>83</sup>                 | 30   | DD/ID     | Idiopathic MR with some dysmorphic features   | G-banded karyotype  | 16.7     |
| Rosenberg et al (2006) <sup>84</sup>              | 81   | DD/ID     | Idiopathic MR and CA  | Karyotype   | 16       |
| Shaffer et al (2006) <sup>85</sup>                | 1500 | DD/ID     | Consecutive patients with DD or MR  | Karyotype (94%), FISH (20%) where prior testing available | 5.6      |
| Sharp et al (2006) <sup>86</sup>                  | 290  | DD/ID     | Idiopathic MR with or without dysmorphism or MCA  | Karyotype, subtelomere FISH (n=255)                       | 5.5      |
| de Vries et al (2005) <sup>87</sup>               | 100  | DD/ID     | Idiopathic MR   | G-banded karyotype, subtelomere MPLA                      | 10       |
| Schoumans et al (2005) <sup>88</sup>              | 41   | DD/ID     | Mild-to-severe idiopathic MR and dysmorphism and/or family history; patients scored >3 on de Vries Checklist (2001) | Spectral karyotype (n=11), subtelomere FISH (n=30)        | 9.8      |
| Tyson et al (2005) <sup>89</sup>                  | 22   | DD/ID     | Mild-to-moderate MR and nonsyndromic dysmorphic features; patients scored >3 on de Vries Checklist (2001)           | G-banded karyotype, subtelomere FISH (n=13)               | 13.6     |
| Harada et al (2004) <sup>90</sup>                 | 69   | DD/ID     | Idiopathic MR, with or without MCA  | Karyotype (400-band level)                                | 5.8      |
| Shaw-Smith et al (2004) <sup>91</sup>             | 50   | DD/ID     | Idiopathic MR and dysmorphism or other features   | Karyotype, subtelomere (n=41)                             | 14       |
| Vissers et al (2003) <sup>92</sup>                | 20   | DD/ID     | Idiopathic MR and dysmorphism; patients scored >3 on de Vries Checklist (2001)                                      | Karyotype   | 10       |

aCGH: array comparative genomic hybridization; AGRE: Autism Genetic Resource Exchange; ASD: autism spectrum disorder; CA: congenital anomaly; DD: developmental delay; EMR: electronic medical record; FISH: fluorescent in situ hybridization; ID: intellectual disability; MCA: multiple congenital anomalies; MLPA: Multiplex Ligation-dependent Probe Amplification; MR: mental retardation; NIMH: National Institute of Mental Health.

Six additional studies published after 2015 are summarized in Table 4.<sup>93,94,95,96,97,98</sup> The diagnostic yields were generally higher than in studies conducted prior to 2016. In the first study by Ho et al (2016), the overall detection rate of copy number variant (CNVs) was 29.4 (9.2% pathogenic, 20.2% variant of uncertain significance) in 5487 patients.<sup>97</sup> In the second study by Ho et al (2016), the overall detection rate of CNVs was 28.1% (8.6% pathogenic, 19.4% variant of uncertain significance) in 10,351 consecutive patients, with an average of 1.2 reportable CNVs per individual.<sup>98</sup> The overlap of patients in the 2 reports is unclear.

**Table 4. Diagnostic Yield of Studies of Patients With Developmental Delay, Intellectual Disability, and ASD Published After 2015**

| Study                               | N      | Diagnoses                    | Patient Description   | Previous Normal Studies  | Yield, %  |
|-------------------------------------|--------|------------------------------|---|--|---|
| Chaves et al (2019) <sup>93</sup>   | 420    | DD/ID/facial dysmorphism/ASD | Children in Brazil with neurodevelopment disorders (62% male; mean age, 9.5 y; range 0 to 49 y) | Karotype (n=138)   | <ul style="list-style-type: none"> <li>• 18 (all)</li> </ul>  |
| Hu et al (2019) <sup>94</sup>       | 633    | DD/ID/ASD                    | Children in China with DD/ID/ASD (359 males, 274 females; age range, 3 mo to 17 y)              | Uncertain  | <ul style="list-style-type: none"> <li>• 20.06 (all)</li> </ul>   |
| Xu et al (2018) <sup>95</sup>       | 434    | DD/ID/ASD                    | Children in China with DD/ID/ASD (371 boys, 63 girls; mean age, 6 y; range, 4 mo to 17 y)       | Uncertain  | <ul style="list-style-type: none"> <li>• 13.6 (all)</li> <li>• 14.7 (excluding ASD)</li> <li>• 12 (only ASD)</li> </ul> |
| Sansovic et al (2017) <sup>96</sup> | 337    | DD/ID/ASD or CAs             | Children in Croatia with DD/ID/ASD or CA (median age, 7 y; range, 1 mo to 25 y)                 | Some patients had previous classical cytogenetic and molecular cytogenetic methods | <ul style="list-style-type: none"> <li>• 21.6 (all)</li> </ul>  |
| Ho et al (2016) <sup>97</sup>       | 5487   | DD/ID/ASD                    | DD/ID/ASD with or without multiple CAs, speech/language delay                                   | Uncertain  | <ul style="list-style-type: none"> <li>• 29.4 (all)</li> <li>• 33 (excluding ASD)</li> <li>• 25 (only ASD)</li> </ul>   |
| Ho et al (2016) <sup>98</sup>       | 10,351 | DD/ID/ASD or multiple CAs    | DD/ID/ASD or multiple CAs   | Uncertain  | <ul style="list-style-type: none"> <li>• 28.1 (all)</li> <li>• 33 (excluding ASD)</li> <li>• 24.4 (only ASD)</li> </ul> |

ASD: autism spectrum disorder; CA: congenital anomaly; DD: developmental delay; ID: intellectual disability.

Studies that reported on diagnostic yield for congenital anomalies are summarized in Table 5. No studies were identified that evaluated the diagnostic yield of CMA for idiopathic language delay.

**Table 5. Diagnostic Yield Studies in Patients With Congenital Anomalies**

| Study                          | N   | Diagnoses                | Patient Description   | Previous Normal Studies | Yield  |
|--------------------------------|-----|--------------------------|---|-------------------------|--|
| Hu et al (2016) <sup>99</sup>  | 119 | Idiopathic short stature | Height of the individual is below 2 SDS of the corresponding mean height for a given age, sex, and population group, and no known causes can be found | Uncertain               | 3/119 (2.5%) identified with a pathogenic CNV  |
| Lu et al (2008) <sup>100</sup> | 638 | Birth defects            | Neonates with possible chromosomal abnormality, ambiguous genitalia, dysmorphic features, multiple congenital anomalies, congenital heart disease     | Uncertain               | 109 (17.1%) patients were identified with clinically significant CNVs most of which would not have been defined by karyotyping |

CNV: copy number variant; SDS: standard deviation score.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

As noted, CMA testing has a higher diagnostic yield than standard karyotyping, which is an accepted test in the evaluation of developmental delay/intellectual disability, ASD, and congenital anomalies. In some cases, disorders are defined by the presence of a genetic variant or genetic testing can contribute to the diagnosis.

In some cases, a specific diagnosis leads to management changes that are either standard of care or are likely to lead to improvements in outcomes.

### Changes in Management

A reasonable body of literature has evaluated whether the establishment of a definitive diagnosis in patients with developmental delay/intellectual disability, ASD, and/or congenital anomalies leads to changes in management that are likely to improve outcomes. Of particular interest is the use of CMA testing to make a specific genetic diagnosis in a patient with developmental delay/intellectual disability, ASD, and/or congenital anomalies is the effect of that diagnosis on the patient's family. Because many affected patients will be evaluated for testing in childhood, the implications of testing on family members and the reciprocal effect on the patient are considerations.

Results of 6 retrospective studies that examined the potential impact of CMA results on clinical decisions are summarized in Table 6. These studies collectively indicate that identified pathogenic variants can prompt clinical actions potentially impacting morbidity. Less clear is how often outcomes will be improved and in which cases interventions might have occurred in the absence of testing. The proportion that may benefit will depend on the variants identified as well as diagnostic yield, which in turn depends on phenotype severity. Studies did not report on any follow-up or

management changes in patients without identified pathogenic variants. In addition to reducing morbidity, bringing closure to a diagnostic odyssey is a reason for genetic testing cited by parents<sup>101</sup> and noted as an outcome in case series and reports.<sup>102</sup> For example, Turner et al (2008) found a median of 16.5 years from the initial medical contact to identify a causal variant in 38 extended families with fragile X syndrome.<sup>103</sup> Saam et al (2008) noted that CMA testing may influence that odyssey.<sup>66</sup> Parents cite obtaining services and support as a reason for testing but how the frequency can impact outcomes is difficult to quantify. The studies reviewed convey a set of intermediate outcomes likely to favorably affect the health of some children. Lacking are end-to-end studies following children at presentation to final outcomes. In addition to these studies, Lingen et al (2016) has reported a benefit for maternal quality of life if aCGH tests succeed to clarify the etiologic diagnosis in an affected child.<sup>104</sup>

**Table 6. Studies Reporting Management Changes After CMA Testing**

| Study                                | Dates Testing | Patients (Tests)                                   | Diagnostic Yield, n (%) or %                  | Pathogenic, n                        | Actionable, n (%)   | Clinical Management Changes, n (%)   |
|--------------------------------------|---------------|--|---|--------------------------------------|---|--|
| Hayeems et al (2015) <sup>105</sup>  | 2009-2011     | 752 (DD and/or CA)                                 | 114 (15.2) <sup>f</sup> 72 (9.6) <sup>g</sup> | 114                                  | <ul style="list-style-type: none"> <li>79.6% (364/457) with reportable results</li> <li>62.4% (184/295) with benign results received medical recommendations</li> </ul> | <ul style="list-style-type: none"> <li>Specialist consults: 221 (37.7)</li> <li>Imaging: 125 (21.3)</li> <li>Lab tests: 70 (12.0)</li> <li>Surveillance: 88 (15.0)</li> <li>Family: 82 (14.0)</li> </ul>                             |
| Henderson et al (2014) <sup>34</sup> | 2009-2012     | 1780 (DD/ID/ASD (81.5% of 227 abnormal))           | 12.7  | 187                                  | 102 (54.5)  | <ul style="list-style-type: none"> <li>Referral: 84 (44.9)</li> <li>Screening: 11 (5.9)</li> <li>Imaging: 38 (20.3)</li> <li>Lab tests: 29 (15.5)</li> </ul>   |
| Tao et al (2014) <sup>42</sup>       | 2011-2013     | 327 DD/ID/ASD                                      | 11.3  | 9 <sup>e</sup>                       | 6 (66.7)  |  |
| Ellison et al (2012) <sup>106</sup>  | 2004-2011     | 46,298 DD/ID, dysmorphic, neuro-behavioral, others | 5.4   | 1259                                 | 441 (35) <sup>d</sup>   | Clinically actionable responses included additional specific tests for monitoring specific disorders.  |
| Coulter et al (2011) <sup>54</sup>   | 2009-2010     | 1792 DD/ID/ASD or CA                               | 7.3 <sup>a</sup> 5.8 <sup>b</sup>             | 121 <sup>a,c</sup> 73 <sup>a,c</sup> | 65 (53.7) <sup>a</sup> 25 (34.2) <sup>b</sup>   | <ul style="list-style-type: none"> <li>Referral: 67 (60)<sup>a</sup> and 11 (29)<sup>b</sup></li> <li>Imaging: 25 (22)<sup>a</sup> and 9 (24)<sup>b</sup></li> <li>Lab tests: 20 (18)<sup>a</sup> and 18 (47)<sup>b</sup></li> </ul> |

| Study                           | Dates Testing | Patients (Tests) | Diagnostic Yield, n (%) or % | Pathogenic, n | Actionable, n (%) | Clinical Management Changes, n (%)   |
|---------------------------------|---------------|------------------|------------------------------|---------------|-------------------|--|
| Saam et al (2008) <sup>66</sup> | 2005-2007     | 490 DD/ID        | 17.6                         | 48            | 34 (70.8)         | <ul style="list-style-type: none"> <li>• Referral: 7 (14.6)</li> <li>• Screening: 8 (16.7)</li> <li>• Avoid further genetic testing: 12 (25)</li> <li>• Improved access to services: 12 (25)</li> <li>• Reproductive recurrence risk: 17 (35.4)</li> </ul> |

ASD: autism spectrum disorder; CA: congenital anomaly; CMA: chromosomal microarray; DD: developmental delay; ID: intellectual disability.

<sup>a</sup> Abnormal.

<sup>b</sup> Possibly significant.

<sup>c</sup> Percentages as reported in the publication-denominators varied from 121 and 73.

<sup>d</sup> Assumed to be from pathogenic results oligonucleotide arrays.

<sup>e</sup> Of the 215 patients with DD/ID or ASD.

<sup>f</sup> Clinically significant.

<sup>g</sup> Uncertain, likely clinically significant.

### Reproductive Decision Making

Risk estimates for recurrence of disease in future births can be altered considerably by information from the genetic diagnosis (see Table 7). Having a child with ASD appears to impact reproductive decision-making or so-called reproductive stoppage. For example, Hoffmann et al (2014) examined reproductive stoppage in families with ASD using the California Department of Developmental Services database linked to birth certificates.<sup>107</sup> Between 1990 and 2003, 19,710 families with 39,361 siblings and half-siblings were identified. Birth histories in these families were then compared with a control group (matched 2:1 by sex, birth year, maternal age, ethnicity/race, and county). Investigators found fertility rates in case and control families similar in the 2 years following the birth of a child with ASD, but, in the subsequent years, the rate was 33% (95% confidence interval [CI], 30% to 37%) lower in families having a child affected by ASD.

**Table 7. Sibling Recurrence Risk After Identification of Different Types of Genomic Abnormalities Associated With ASD**

| Type of Genetic Abnormality                        | Clinical Example   | Sibling Recurrence Risk   |
|--|--|---|
| Dominant single-gene disorder with full penetrance | Tuberous sclerosis: involves abnormalities of the skin, brain, and heart; associated with ID and ASD | 50% if parent carries the disease-causing variant (i.e., not a de novo variant) |
| Recessive single-gene disorder                     | Smith-Lemli-Opitz syndrome: congenital multiple anomaly syndrome; associated with ASD                | 25%   |
| X-linked single-gene disorder                      | Fragile X syndrome: most common cause of mental retardation; associated with ASD                     | Brother: 50%<br>Sister: up to 50% will be carriers or might be mildly affected  |
| Copy number variant                                | Prader-Willi syndrome/Angelman syndrome (15q11-q13 duplication)                                      | Same as population prevalence if de novo (i.e., not found in parents)           |

ASD: autism spectrum disorder; ID: intellectual disability.

### **Section Summary: Chromosomal Microarray Testing**

The evidence for use of CMA testing for a definitive diagnosis in individuals with developmental delay/intellectual disability, ASD, and/or congenital anomalies consists of studies reporting on the yield of a positive test in affected individuals, combined with a chain of evidence to support the clinical utility of testing. The testing yield varies by the underlying population tested, but is generally higher than 10%, with higher rates in patients with congenital anomalies. While direct evidence of improved outcomes with CMA compared with karyotype is lacking, for at least a subset of the disorders potentially diagnosed with CMA in this patient population, there are well-defined and accepted management steps associated with positive test results. Further, there is evidence of changes in reproductive decision-making as a result of positive test results. For children with idiopathic growth or language delay, clinical validity has not been established and there is no direct or indirect evidence to support clinical utility.

### **Next-Generation Sequencing Panel Testing Clinical Context and Test Purpose**

The purpose of gene panel testing with next-generation sequencing is to identify a genetic cause for individuals with developmental delay/intellectual disability, ASD, and congenital anomalies. A genetic diagnosis may end a diagnostic odyssey, improve treatment, facilitate the management of associated medical conditions, and permit carrier testing to assess risks to future offspring.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is children with developmental delay/intellectual disability, ASD, and congenital anomalies for whom the cause of the disorder has not been identified after CMA testing.

#### ***Interventions***

The relevant intervention of interest is gene panel testing with next-generation sequencing. Referral for genetic counseling is important for the explanation of the genetic disease, heritability, genetic risk, test performance, and possible outcomes.

#### ***Comparators***

The following test is currently being used to diagnose developmental delay/intellectual disability, ASD, and congenital anomalies: CMA testing. Referral for genetic counseling is important for the explanation of the genetic disease, heritability, genetic risk, test performance, and possible outcomes.

#### ***Outcomes***

The potential beneficial outcomes of interest are the identification of genetic bases of the disorder, avoidance of future testing, changes in management that lead to an improvement in health outcomes, and identification of unaffected carriers.

Potential harmful outcomes are those resulting from a false-positive or false-negative test result. False-positive test results can lead to an incorrect diagnosis and inappropriate treatment. False-negative test results can lead to the absence of appropriate treatment and continuation of the diagnostic odyssey.

Follow-up to monitor for outcomes varies from immediately following testing to identify diagnostic accuracy to long-term health outcomes subsequent to management changes.

### **Study Selection Criteria**

For the evaluation of clinical validity of the gene panel testing with next-generation sequencing, studies that met the following eligibility criteria were considered:

- case series or cohort studies that enrolled 20 or more patients with clinical diagnoses of developmental delay/intellectual disability or ASD with known or suspicion of genetic abnormalities, with or without negative results by CMA testing on enrolled patients, or
- examined management decisions and/or patient outcomes based on genetic evaluation results.

### Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### Systematic Review

Furley et al (2025) conducted a systematic review and meta-analysis to evaluate the diagnostic yield of investigations requested for children with different presentations for symptoms of neurodevelopmental delay and/or developmental regression.<sup>108</sup> Fifteen publications of children  $\geq$  18 years of age with symptoms of developmental regression, defined as a reported loss of established skill(s) in at least 1 of any of these domains: speech/language, fine and or gross motor, social, cognitive and or functional abilities, without an explanatory diagnosis were included in the meta-analysis. Children were grouped into 4 distinct categories: neurodevelopmental disability (NDD), developmental epileptic encephalopathy (DEE), suspected genetic condition-Rett syndrome, and suspected metabolic conditions - inborn error of metabolism (IEM), with further subdivision of the NDD category; NDD-delay refers to children who were not reaching age expected abilities in any developmental domain, children with NDD and autism with and without developmental delays were grouped as NDD-autism, and children with NDD and undifferentiated neurological symptoms were grouped as NDD-neuro. The type of investigations were also divided into 4 categories (genetic/genomic, metabolic, neuroimaging, and neurophysiology). The diagnostic yield for genetic/genomic investigations, which include next-generation sequencing [NGS], whole exome sequencing [WES] and mitochondrial disorder gene panels, was 70% (6 studies, N=142, 95% confidence interval [CI]: 47 to 92), compared with 28% for metabolic (5 studies, N=286, 95% CI: 0 to 64), 13% neurophysiological (2 studies, N=127, 95% CI: 0 to 39), and 6% for neuroimaging (2 studies, N=41, 95% CI: 0 to 10). Notable limitations include, but are not limited to, overlapping symptoms betwixt conditions, no definitive definition of developmental regression, small sample size, and inter- and intra-heterogeneity within the included studies.

### Case Series or Cohort Studies

Several studies have assessed next-generation sequencing panel testing on samples from patients with intellectual disability with negative aCGH testing. Table 8 summarizes the diagnostic yield. For example, Grozeva et al (2016) reported that next-generation sequencing targeted testing resulted in an 11% additional diagnostic yield beyond the 10% to 15% yield from aCGH alone.<sup>109</sup> However, Kalsner et al (2018) reported no increase in yield using a next-generation sequencing panel.<sup>110</sup>

**Table 8. Diagnostic Yield Studies Published**

| Study                               | N   | Diagnoses | Patient Description  | Previous Normal Studies         | Yield  |
|-------------------------------------|-----|-----------|--|---------------------------------|--|
| Kalsner et al (2018) <sup>110</sup> | 100 | ASD       | Consecutive children referred to a single U.S. neurogenetics clinic with a confirmed diagnosis of ASD without a known genetic diagnosis suspected to be causative of ASD | Performed concurrently with CMA | CMA yield: 12% (included pathogenic CNVs and VUS) NGS panel yield: 11% (included pathogenic or likely pathogenic variants [VUS likely pathogenic]) |

| Study                               | N   | Diagnoses | Patient Description   | Previous Normal Studies  | Yield   |
|-------------------------------------|-----|-----------|---|--|---|
| Grozeva et al (2015) <sup>109</sup> | 986 | M-to-S ID | 996 patients with M-to-S ID from the U.K. (70%), Australia, Spain, U.S., and Italy. Studied phenotypes included: 905 cases with CHD; 911 cases with ciliopathy, coloboma, neuromuscular disease, severe insulin resistance, congenital thyroid disease. | Negative CMA testing at 500 kb resolution, and testing for fragile X and Prader-Willi or Angelman syndrome | 11% had likely pathogenic rare variant (8% had likely pathogenic loss-of-function variant and 3% had known pathogenic missense variant) |
| Redin et al (2014) <sup>39</sup>    | 166 | ID        | ID patients with or without associated autistic-like features, fragile X, and other specific genetic conditions   | Negative for aCGH  | Overall diagnostic yield: 25%, with 26 causative variants (16 X-linked, 10 de novo in autosomal-dominant genes)                         |

aCGH: array comparative genomic hybridization; ASD: autism spectrum disorder; CHD: congenital heart disease; CMA: chromosomal microarray; CNV: copy number variant; ID: intellectual disability; M-to-S: moderate-to-severe; NGS: next-generation sequencing; VUS: variant of uncertain significance.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

No peer-reviewed, full-length randomized trials on the clinical utility of the commercially available next-generation sequencing panels for developmental delay/intellectual disability or ASD were identified.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of next-generation sequencing testing in these populations has not been established, a chain of evidence supporting the clinical utility of next-generation sequencing cannot be constructed.

### Section Summary: Next-Generation Sequencing Panel Testing

It is arguable that a chain of evidence for the use of CMA testing in evaluating developmental delay/intellectual disability, ASD, and/or congenital anomalies would apply to next-generation sequencing panels. However, the clinical validity of next-generation sequencing panels is less well-established than for CMA. The testing yield and likelihood of an uncertain result are variable, based on the gene panel, gene tested, and patient population. There are real risks of uninterpretable and incidental results. Therefore, current evidence does not permit conclusions on whether next-generation sequencing panel testing improves outcomes.

### Summary of Evidence

For individuals who have developmental delay/intellectual disability, autism spectrum disorder (ASD), or multiple congenital anomalies not specific to a well-delineated genetic syndrome who receive chromosomal microarray (CMA) testing, the evidence includes primarily case series. Relevant outcomes are test validity, changes in reproductive decision making, morbid events, and resource utilization. The available evidence supports test validity. Although systematic studies of the impact of CMA on patient outcomes are lacking, the improvement in diagnostic yield over karyotyping has been well-demonstrated. Direct evidence of improved outcomes with CMA compared with karyotyping is also lacking. However, for at least a subset of the disorders potentially diagnosed with CMA testing in this patient population, there are well-defined and accepted management steps associated with positive test results. Further, there is evidence of changes in reproductive decision-making as a result of positive test results. The information derived from CMA testing can accomplish the following: it could end a long diagnostic odyssey, reduce morbidity for certain conditions by initiating surveillance/management of associated comorbidities, or it could impact future reproductive decision making for parents. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have developmental delay/intellectual disability, ASD, or multiple congenital anomalies not specific to a well-delineated genetic syndrome who receive next-generation sequencing panel testing, the evidence includes primarily case series and 1 systematic review. Relevant outcomes are test validity, changes in reproductive decision-making, morbid events, and resource utilization. The diagnostic yield associated with next-generation sequencing panel testing in this patient population is not well-characterized. The testing yield and likelihood of an uncertain result are variable, based on the gene panel, gene tested, and patient population; additionally, there are risks of uninterpretable and incidental results. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### American Academy of Child and Adolescent Psychiatry

In 2014, the American Academy of Child and Adolescent Psychiatry updated its guidelines on the assessment and treatment of children and adolescents with autism spectrum disorder (ASD).<sup>111</sup> The Academy recommended that "all children with ASD should have a medical assessment, which typically includes physical examination, a hearing screen, a Wood's lamp examination for signs of tuberous sclerosis, and genetic testing, which may include G-banded karyotype, fragile X testing, or chromosomal microarray."

#### American Academy of Neurology and Child Neurology Society

In 2011, the American Academy of Neurology and the Child Neurology Society updated their guidelines on the evaluation of unexplained developmental delay and intellectual disability with information on genetic and metabolic (biochemical) testing to accommodate advances in the field.<sup>112</sup> The guidelines concluded that CMA testing has the highest diagnostic yield in children with developmental delay/intellectual disability, that the "often complex results require confirmation and careful interpretation, often with the assistance of a medical geneticist," and that CMA should be

considered the “first-line” test. The guidelines acknowledged that “Research is sorely lacking on the medical, social, and financial benefits of having an accurate etiologic diagnosis.”

### **American Academy of Pediatrics**

In 2014, the American Academy of Pediatrics (AAP) issued a clinical report on the optimal medical genetics evaluation of a child with developmental delays or intellectual disability.<sup>15</sup> Regarding chromosomal microarray (CMA) testing, this report stated: “CMA now should be considered a first-tier diagnostic test in all children with [global developmental delay/intellectual disability] GDD/ID for whom the causal diagnosis is not known.... CMA is now the standard for diagnosis of patients with GDD/ID, as well as other conditions, such as autism spectrum disorders or multiple congenital anomalies.”

In 2020, the AAP issued a clinical report on identifying infants and young children with developmental disorders through surveillance and screening.<sup>13</sup> The report proposed a screening model that included performing a complete medical evaluation and stated that: “A child with suspected global developmental delay or intellectual disability should have laboratory testing done, including chromosomal microarray and fragile X testing [...] Further testing may be indicated when a diagnosis is not established with initial laboratory evaluation including whole exome sequencing and gene panels.”

### **American College of Medical Genetics**

The American College of Medical Genetics (ACMG) (2021) published a clinical practice resource on the use of exome and genome sequencing (ES/GS) technologies in the care of pediatric patients with one or more congenital anomalies (CA) with onset prior to age 1 year or developmental delay (DD) or intellectual disability (ID) with onset prior to age 18 years.<sup>14,15</sup> The guideline states: “We strongly recommend ES and GS as a first-tier or second-tier test (guided by clinical judgment and often clinician–patient/family shared decision making after CMA or focused testing) for patients with one or more CAs prior to one year of age or for patients with DD/ID with onset prior to 18 years of age.”

The American College of Medical Genetics (ACMG) (2010; reaffirmed 2020) published a clinical practice resource on array-based technologies and their clinical utilization for detecting chromosomal abnormalities.<sup>16,17</sup> CMA testing for copy number variants was recommended as a first-line test in the initial postnatal evaluation of individuals with the following:

- Multiple anomalies not specific to a well-delineated genetic syndrome
- Apparently nonsyndromic developmental delay/intellectual disability
- Autism spectrum disorder (ASD)

Other ACMG guidelines have addressed the design and performance expectations for clinical microarrays and associated software<sup>8,118</sup> and for the interpretation and reporting of copy number variants,<sup>11</sup> both intended for the postnatal setting.

A 2013 update included recommendations on the validation of microarray methodologies for both prenatal and postnatal specimens.<sup>119</sup> The guideline revisions from ACMG (2013) stated that a stepwise or tiered approach to the clinical genetic diagnostic evaluation of ASD is recommended, with the first tier including fragile X syndrome and CMA, and the second tier *MECP2* and *PTEN* testing.<sup>120</sup> The guidelines stated that: “this approach will evolve with continued advancements in diagnostic testing and improved understanding of the ASD phenotype. Multiple additional conditions have been reported in association with an ASD phenotype, but none of these has been evaluated in a large prospective cohort. Therefore, a future third tier of evaluation is a distinct possibility. Further studies would be needed to elevate the evidence to the point of recommended testing. Alternatively, advances in technology may permit bundling of individual tests into an extended, more readily accessible, and less expensive platform. The accumulating evidence using next-generation sequencing (third-tier testing) will increase the diagnostic yield even more over the next few years.”

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**Ongoing and Unpublished Clinical Trials**

**Table 9. Summary of Key Clinical Trials**

| NCT No.        | Trial Name  | Planned Enrollment | Completion Date |
|----------------|---|--------------------|-----------------|
| <i>Ongoing</i> |   |                    |                 |
| NCT04727489    | Study of the Genetic Factors Involved in Autism and Related Disorders   | 3800               | Mar. 2036       |
| NCT05480826    | Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression | 50                 | Sep. 2028       |

**References**

1. Mikhail FM, Lose EJ, Robin NH, et al. Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. *Am J Med Genet A*. Oct 2011; 155A(10): 2386-96. PMID 22031302
2. Brandler WM, Sebat J. From de novo mutations to personalized therapeutic interventions in autism. *Annu Rev Med*. 2015; 66: 487-507. PMID 25587659
3. Stankiewicz P, Beaudet AL. Use of array CGH in the evaluation of dysmorphism, malformations, developmental delay, and idiopathic mental retardation. *Curr Opin Genet Dev*. Jun 2007; 17(3): 182-92. PMID 17467974
4. Stuart SW, King CH, Pai GS. Autism spectrum disorder, Klinefelter syndrome, and chromosome 3p21.31 duplication: a case report. *MedGenMed*. Dec 18 2007; 9(4): 60. PMID 18311409
5. Moeschler JB. Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability. *Curr Opin Neurol*. Apr 2008; 21(2): 117-22. PMID 18317267
6. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. *Genet Med*. Apr 2008; 10(4): 301-5. PMID 18414214
7. Korf BR, Rehm HL. New approaches to molecular diagnosis. *JAMA*. Apr 10 2013; 309(14): 1511-21. PMID 23571590
8. Kearney HM, South ST, Wolff DJ, et al. American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities. *Genet Med*. Jul 2011; 13(7): 676-9. PMID 21681105
9. Rodríguez-Revenga L, Vallespín E, Madrigal I, et al. A parallel study of different array-CGH platforms in a set of Spanish patients with developmental delay and intellectual disability. *Gene*. May 25 2013; 521(1): 82-6. PMID 23524024
10. Kloosterman WP, Hochstenbach R. Deciphering the pathogenic consequences of chromosomal aberrations in human genetic disease. *Mol Cytogenet*. 2014; 7(1): 100. PMID 25606056
11. Kearney HM, Thorland EC, Brown KK, et al. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med*. Jul 2011; 13(7): 680-5. PMID 21681106

12. Riggs ER, Church DM, Hanson K, et al. Towards an evidence-based process for the clinical interpretation of copy number variation. *Clin Genet*. May 2012; 81(5): 403-12. PMID 22097934
13. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). TEC Special Report: Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Developmental Delay/Mental Retardation and Autism Spectrum Disorder. TEC Assessments. 2009;Volume 24;Tab 10.
14. Blue Cross and Blue Shield Association. Special Report: Chromosomal Microarray for the Genetic Evaluation of Patients With Global Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder. TEC Assessments. 2015;Volume 30;Tab 2.
15. Moeschler JB, Shevell M, Moeschler JB, et al. Comprehensive evaluation of the child with intellectual disability or global developmental delays. *Pediatrics*. Sep 2014; 134(3): e903-18. PMID 25157020
16. Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. *Neurology*. Feb 11 2003; 60(3): 367-80. PMID 12578916
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. Washington (DC): American Psychiatric Association; 2013.
18. Zablotsky B, Black LI, Maenner MJ, et al. Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017. *Pediatrics*. Oct 2019; 144(4). PMID 31558576
19. NCHS Data Brief. Diagnosed Developmental Disabilities in Children Aged 3-17 Years: United States, 2019-2021. <https://www.cdc.gov/nchs/data/databriefs/db473.pdf>. July 2023. Accessed August 2025.
20. Srour M, Shevell M. Genetics and the investigation of developmental delay/intellectual disability. *Arch Dis Child*. Apr 2014; 99(4): 386-9. PMID 24344174
21. Willemsen MH, Kleefstra T. Making headway with genetic diagnostics of intellectual disabilities. *Clin Genet*. Feb 2014; 85(2): 101-10. PMID 23895455
22. Moeschler JB. Genetic evaluation of intellectual disabilities. *Semin Pediatr Neurol*. Mar 2008; 15(1): 2-9. PMID 18342255
23. Yuen RK, Thiruvahindrapuram B, Merico D, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. *Nat Med*. Feb 2015; 21(2): 185-91. PMID 25621899
24. Gaugler T, Klei L, Sanders SJ, et al. Most genetic risk for autism resides with common variation. *Nat Genet*. Aug 2014; 46(8): 881-5. PMID 25038753
25. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. *Genet Med*. Jan 2008; 10(1): 4-12. PMID 18197051
26. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J Med Genet*. Apr 2005; 42(4): 318-21. PMID 15805158
27. Wright CF, Fitzgerald TW, Jones WD, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet*. Apr 04 2015; 385(9975): 1305-14. PMID 25529582
28. Eriksson MA, Liedén A, Westerlund J, et al. Rare copy number variants are common in young children with autism spectrum disorder. *Acta Paediatr*. Jun 2015; 104(6): 610-8. PMID 25661985
29. Krepischi-Santos AC, Vianna-Morgante AM, Jehee FS, et al. Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations. *Cytogenet Genome Res*. 2006; 115(3-4): 254-61. PMID 17124408
30. Bartnik M, Nowakowska B, Derwińska K, et al. Application of array comparative genomic hybridization in 256 patients with developmental delay or intellectual disability. *J Appl Genet*. Feb 2014; 55(1): 125-44. PMID 24297458
31. Bartnik M, Wiśniowiecka-Kowalnik B, Nowakowska B, et al. The usefulness of array comparative genomic hybridization in clinical diagnostics of intellectual disability in children. *Dev Period Med*. 2014; 18(3): 307-17. PMID 25182394

32. Chong WW, Lo IF, Lam ST, et al. Performance of chromosomal microarray for patients with intellectual disabilities/developmental delay, autism, and multiple congenital anomalies in a Chinese cohort. *Mol Cytogenet.* 2014; 7: 34. PMID 24926319
33. D'Amours G, Langlois M, Mathonnet G, et al. SNP arrays: comparing diagnostic yields for four platforms in children with developmental delay. *BMC Med Genomics.* Dec 24 2014; 7: 70. PMID 25539807
34. Henderson LB, Applegate CD, Wohler E, et al. The impact of chromosomal microarray on clinical management: a retrospective analysis. *Genet Med.* Sep 2014; 16(9): 657-64. PMID 24625444
35. Nava C, Keren B, Mignot C, et al. Prospective diagnostic analysis of copy number variants using SNP microarrays in individuals with autism spectrum disorders. *Eur J Hum Genet.* Jan 2014; 22(1): 71-8. PMID 23632794
36. Nicholl J, Waters W, Mulley JC, et al. Cognitive deficit and autism spectrum disorders: prospective diagnosis by array CGH. *Pathology.* Jan 2014; 46(1): 41-5. PMID 24300712
37. Palmer E, Speirs H, Taylor PJ, et al. Changing interpretation of chromosomal microarray over time in a community cohort with intellectual disability. *Am J Med Genet A.* Feb 2014; 164A(2): 377-85. PMID 24311194
38. Preiksaitiene E, Molytė A, Kasnauskiene J, et al. Considering specific clinical features as evidence of pathogenic copy number variants. *J Appl Genet.* May 2014; 55(2): 189-96. PMID 24535828
39. Redin C, Gérard B, Lauer J, et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. *J Med Genet.* Nov 2014; 51(11): 724-36. PMID 25167861
40. Roberts JL, Hovanes K, Dasouki M, et al. Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders or learning disability presenting for genetic services. *Gene.* Feb 01 2014; 535(1): 70-8. PMID 24188901
41. Stobbe G, Liu Y, Wu R, et al. Diagnostic yield of array comparative genomic hybridization in adults with autism spectrum disorders. *Genet Med.* Jan 2014; 16(1): 70-7. PMID 23765050
42. Tao VQ, Chan KY, Chu YW, et al. The clinical impact of chromosomal microarray on paediatric care in Hong Kong. *PLoS One.* 2014; 9(10): e109629. PMID 25333781
43. Utine GE, Haliloğlu G, Volkan-Salançı B, et al. Etiological yield of SNP microarrays in idiopathic intellectual disability. *Eur J Paediatr Neurol.* May 2014; 18(3): 327-37. PMID 24508361
44. Uwineza A, Caberg JH, Hitayezu J, et al. Array-CGH analysis in Rwandan patients presenting development delay/intellectual disability with multiple congenital anomalies. *BMC Med Genet.* Jul 12 2014; 15: 79. PMID 25016475
45. Battaglia A, Doccini V, Bernardini L, et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. *Eur J Paediatr Neurol.* Nov 2013; 17(6): 589-99. PMID 23711909
46. Lee CG, Park SJ, Yun JN, et al. Array-based comparative genomic hybridization in 190 Korean patients with developmental delay and/or intellectual disability: a single tertiary care university center study. *Yonsei Med J.* Nov 2013; 54(6): 1463-70. PMID 24142652
47. Shoukier M, Klein N, Auber B, et al. Array CGH in patients with developmental delay or intellectual disability: are there phenotypic clues to pathogenic copy number variants?. *Clin Genet.* Jan 2013; 83(1): 53-65. PMID 22283495
48. Sorte HS, Gjevik E, Sponheim E, et al. Copy number variation findings among 50 children and adolescents with autism spectrum disorder. *Psychiatr Genet.* Apr 2013; 23(2): 61-9. PMID 23277134
49. Filges I, Suda L, Weber P, et al. High resolution array in the clinical approach to chromosomal phenotypes. *Gene.* Mar 10 2012; 495(2): 163-9. PMID 22240311

50. Iourov IY, Vorsanova SG, Kurinnaia OS, et al. Molecular karyotyping by array CGH in a Russian cohort of children with intellectual disability, autism, epilepsy and congenital anomalies. *Mol Cytogenet.* Dec 31 2012; 5(1): 46. PMID 23272938
51. McGrew SG, Peters BR, Crittendon JA, et al. Diagnostic yield of chromosomal microarray analysis in an autism primary care practice: which guidelines to implement?. *J Autism Dev Disord.* Aug 2012; 42(8): 1582-91. PMID 22089167
52. Tzetzis M, Kitsiou-Tzeli S, Frysira H, et al. The clinical utility of molecular karyotyping using high-resolution array-comparative genomic hybridization. *Expert Rev Mol Diagn.* Jun 2012; 12(5): 449-57. PMID 22702362
53. Bremer A, Giacobini M, Eriksson M, et al. Copy number variation characteristics in subpopulations of patients with autism spectrum disorders. *Am J Med Genet B Neuropsychiatr Genet.* Mar 2011; 156(2): 115-24. PMID 21302340
54. Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. *Genet Med.* Sep 2011; 13(9): 770-6. PMID 21716121
55. Wincent J, Anderlid BM, Lagerberg M, et al. High-resolution molecular karyotyping in patients with developmental delay and/or multiple congenital anomalies in a clinical setting. *Clin Genet.* Feb 2011; 79(2): 147-57. PMID 20486943
56. Manolakos E, Vetro A, Kefalas K, et al. The use of array-CGH in a cohort of Greek children with developmental delay. *Mol Cytogenet.* Nov 09 2010; 3: 22. PMID 21062444
57. Rosenfeld JA, Ballif BC, Torchia BS, et al. Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders. *Genet Med.* Nov 2010; 12(11): 694-702. PMID 20808228
58. Schaefer GB, Starr L, Pickering D, et al. Array comparative genomic hybridization findings in a cohort referred for an autism evaluation. *J Child Neurol.* Dec 2010; 25(12): 1498-503. PMID 20729506
59. Shen Y, Dies KA, Holm IA, et al. Clinical genetic testing for patients with autism spectrum disorders. *Pediatrics.* Apr 2010; 125(4): e727-35. PMID 20231187
60. Bruno DL, Ganesamoorthy D, Schoumans J, et al. Detection of cryptic pathogenic copy number variations and constitutional loss of heterozygosity using high resolution SNP microarray analysis in 117 patients referred for cytogenetic analysis and impact on clinical practice. *J Med Genet.* Feb 2009; 46(2): 123-31. PMID 19015223
61. Friedman J, Adam S, Arbour L, et al. Detection of pathogenic copy number variants in children with idiopathic intellectual disability using 500 K SNP array genomic hybridization. *BMC Genomics.* Nov 16 2009; 10: 526. PMID 19917086
62. Baldwin EL, Lee JY, Blake DM, et al. Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. *Genet Med.* Jun 2008; 10(6): 415-29. PMID 18496225
63. Christian SL, Brune CW, Sudi J, et al. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. *Biol Psychiatry.* Jun 15 2008; 63(12): 1111-7. PMID 18374305
64. Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet.* Feb 2008; 82(2): 477-88. PMID 18252227
65. Pickering DL, Eudy JD, Olney AH, et al. Array-based comparative genomic hybridization analysis of 1176 consecutive clinical genetics investigations. *Genet Med.* Apr 2008; 10(4): 262-6. PMID 18414209
66. Saam J, Gudgeon J, Aston E, et al. How physicians use array comparative genomic hybridization results to guide patient management in children with developmental delay. *Genet Med.* Mar 2008; 10(3): 181-6. PMID 18344707
67. Shevell MI, Bejjani BA, Srour M, et al. Array comparative genomic hybridization in global developmental delay. *Am J Med Genet B Neuropsychiatr Genet.* Oct 05 2008; 147B(7): 1101-8. PMID 18361433
68. Aradhya S, Manning MA, Splendore A, et al. Whole-genome array-CGH identifies novel contiguous gene deletions and duplications associated with developmental delay, mental

- retardation, and dysmorphic features. *Am J Med Genet A*. Jul 01 2007; 143A(13): 1431-41. PMID 17568414
69. Ballif BC, Sulpizio SG, Lloyd RM, et al. The clinical utility of enhanced subtelomeric coverage in array CGH. *Am J Med Genet A*. Aug 15 2007; 143A(16): 1850-7. PMID 17632771
  70. Froyen G, Van Esch H, Bauters M, et al. Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes. *Hum Mutat*. Oct 2007; 28(10): 1034-42. PMID 17546640
  71. Hoyer J, Dreweke A, Becker C, et al. Molecular karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism arrays. *J Med Genet*. Oct 2007; 44(10): 629-36. PMID 17601928
  72. Lu X, Shaw CA, Patel A, et al. Clinical implementation of chromosomal microarray analysis: summary of 2513 postnatal cases. *PLoS One*. Mar 28 2007; 2(3): e327. PMID 17389918
  73. Madrigal I, Rodríguez-Revenga L, Armengol L, et al. X-chromosome tiling path array detection of copy number variants in patients with chromosome X-linked mental retardation. *BMC Genomics*. Nov 29 2007; 8: 443. PMID 18047645
  74. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. *Science*. Apr 20 2007; 316(5823): 445-9. PMID 17363630
  75. Shen Y, Irons M, Miller DT, et al. Development of a focused oligonucleotide-array comparative genomic hybridization chip for clinical diagnosis of genomic imbalance. *Clin Chem*. Dec 2007; 53(12): 2051-9. PMID 17901113
  76. Thuresson AC, Bondeson ML, Edeby C, et al. Whole-genome array-CGH for detection of submicroscopic chromosomal imbalances in children with mental retardation. *Cytogenet Genome Res*. 2007; 118(1): 1-7. PMID 17901693
  77. Wagenstaller J, Spranger S, Lorenz-Depiereux B, et al. Copy-number variations measured by single-nucleotide-polymorphism oligonucleotide arrays in patients with mental retardation. *Am J Hum Genet*. Oct 2007; 81(4): 768-79. PMID 17847001
  78. Ballif BC, Rorem EA, Sundin K, et al. Detection of low-level mosaicism by array CGH in routine diagnostic specimens. *Am J Med Genet A*. Dec 15 2006; 140(24): 2757-67. PMID 17103431
  79. Friedman JM, Baross A, Delaney AD, et al. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. *Am J Hum Genet*. Sep 2006; 79(3): 500-13. PMID 16909388
  80. Jacquemont ML, Sanlaville D, Redon R, et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. *J Med Genet*. Nov 2006; 43(11): 843-9. PMID 16840569
  81. Lugtenberg D, de Brouwer AP, Kleefstra T, et al. Chromosomal copy number changes in patients with non-syndromic X linked mental retardation detected by array CGH. *J Med Genet*. Apr 2006; 43(4): 362-70. PMID 16169931
  82. Menten B, Maas N, Thienpont B, et al. Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. *J Med Genet*. Aug 2006; 43(8): 625-33. PMID 16490798
  83. Miyake N, Shimokawa O, Harada N, et al. BAC array CGH reveals genomic aberrations in idiopathic mental retardation. *Am J Med Genet A*. Feb 01 2006; 140(3): 205-11. PMID 16419101
  84. Rosenberg C, Knijnenburg J, Bakker E, et al. Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. *J Med Genet*. Feb 2006; 43(2): 180-6. PMID 15980116
  85. Shaffer LG, Kashork CD, Saleki R, et al. Targeted genomic microarray analysis for identification of chromosome abnormalities in 1500 consecutive clinical cases. *J Pediatr*. Jul 2006; 149(1): 98-102. PMID 16860135

86. Sharp AJ, Hansen S, Selzer RR, et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. *Nat Genet.* Sep 2006; 38(9): 1038-42. PMID 16906162
87. de Vries BB, Pfundt R, Leisink M, et al. Diagnostic genome profiling in mental retardation. *Am J Hum Genet.* Oct 2005; 77(4): 606-16. PMID 16175506
88. Schoumans J, Ruivenkamp C, Holmberg E, et al. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). *J Med Genet.* Sep 2005; 42(9): 699-705. PMID 16141005
89. Tyson C, Harvard C, Locker R, et al. Submicroscopic deletions and duplications in individuals with intellectual disability detected by array-CGH. *Am J Med Genet A.* Dec 15 2005; 139(3): 173-85. PMID 16283669
90. Harada N, Hatchwell E, Okamoto N, et al. Subtelomere specific microarray based comparative genomic hybridisation: a rapid detection system for cryptic rearrangements in idiopathic mental retardation. *J Med Genet.* Feb 2004; 41(2): 130-6. PMID 14757861
91. Shaw-Smith C, Redon R, Rickman L, et al. Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. *J Med Genet.* Apr 2004; 41(4): 241-8. PMID 15060094
92. Vissers LE, de Vries BB, Osoegawa K, et al. Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. *Am J Hum Genet.* Dec 2003; 73(6): 1261-70. PMID 14628292
93. Chaves TF, Baretto N, Oliveira LF, et al. Copy Number Variations in a Cohort of 420 Individuals with Neurodevelopmental Disorders From the South of Brazil. *Sci Rep.* Nov 28 2019; 9(1): 17776. PMID 31780800
94. Hu T, Zhang Z, Wang J, et al. Chromosomal Aberrations in Pediatric Patients with Developmental Delay/Intellectual Disability: A Single-Center Clinical Investigation. *Biomed Res Int.* 2019; 2019: 9352581. PMID 31781653
95. Xu M, Ji Y, Zhang T, et al. Clinical Application of Chromosome Microarray Analysis in Han Chinese Children with Neurodevelopmental Disorders. *Neurosci Bull.* Dec 2018; 34(6): 981-991. PMID 29948840
96. Sansović I, Ivankov AM, Bobinec A, et al. Chromosomal microarray in clinical diagnosis: a study of 337 patients with congenital anomalies and developmental delays or intellectual disability. *Croat Med J.* Jun 14 2017; 58(3): 231-238. PMID 28613040
97. Ho KS, Twede H, Vanzo R, et al. Clinical Performance of an Ultrahigh Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders. *Biomed Res Int.* 2016; 2016: 3284534. PMID 27975050
98. Ho KS, Wassman ER, Baxter AL, et al. Chromosomal Microarray Analysis of Consecutive Individuals with Autism Spectrum Disorders Using an Ultra-High Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders. *Int J Mol Sci.* Dec 09 2016; 17(12). PMID 27941670
99. Hu G, Fan Y, Wang L, et al. Copy number variations in 119 Chinese children with idiopathic short stature identified by the custom genome-wide microarray. *Mol Cytogenet.* 2016; 9: 16. PMID 26884814
100. Lu XY, Phung MT, Shaw CA, et al. Genomic imbalances in neonates with birth defects: high detection rates by using chromosomal microarray analysis. *Pediatrics.* Dec 2008; 122(6): 1310-8. PMID 19047251
101. Gogarty B. Parents as partners. A report and guidelines on the investigation of children with developmental delay; by parents, for professionals Cambridge: Cambridge Genetics Knowledge Park; 2006.
102. Mroch AR, Flanagan JD, Stein QP. Solving the puzzle: case examples of array comparative genomic hybridization as a tool to end the diagnostic odyssey. *Curr Probl Pediatr Adolesc Health Care.* Mar 2012; 42(3): 74-8. PMID 22325475

103. Turner G, Boyle J, Partington MW, et al. Restoring reproductive confidence in families with X-linked mental retardation by finding the causal mutation. *Clin Genet*. Feb 2008; 73(2): 188-90. PMID 18070138
104. Lingen M, Albers L, Borchers M, et al. Obtaining a genetic diagnosis in a child with disability: impact on parental quality of life. *Clin Genet*. Feb 2016; 89(2): 258-66. PMID 26084449
105. Hayeems RZ, Hoang N, Chenier S, et al. Capturing the clinical utility of genomic testing: medical recommendations following pediatric microarray. *Eur J Hum Genet*. Sep 2015; 23(9): 1135-41. PMID 25491637
106. Ellison JW, Ravnan JB, Rosenfeld JA, et al. Clinical utility of chromosomal microarray analysis. *Pediatrics*. Nov 2012; 130(5): e1085-95. PMID 23071206
107. Hoffmann TJ, Windham GC, Anderson M, et al. Evidence of reproductive stoppage in families with autism spectrum disorder: a large, population-based cohort study. *JAMA Psychiatry*. Aug 2014; 71(8): 943-51. PMID 24942798
108. Furley K, Teo A, Williams K, et al. The Diagnostic Yield of Investigating Developmental Regression in Children: A Systematic Review and Meta-Analysis. *J Autism Dev Disord*. Feb 20 2025. PMID 39976758
109. Grozeva D, Carss K, Spasic-Boskovic O, et al. Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability. *Hum Mutat*. Dec 2015; 36(12): 1197-204. PMID 26350204
110. Kalsner L, Twachtman-Bassett J, Tokarski K, et al. Genetic testing including targeted gene panel in a diverse clinical population of children with autism spectrum disorder: Findings and implications. *Mol Genet Genomic Med*. Mar 2018; 6(2): 171-185. PMID 29271092
111. Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. Feb 2014; 53(2): 237-57. PMID 24472258
112. Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: Genetic and metabolic testing on children with global developmental delay [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. Oct 25 2011; 77(17): 1629-35. PMID 21956720
113. Lipkin PH, Macias MM, Norwood KW, et al. Promoting Optimal Development: Identifying Infants and Young Children With Developmental Disorders Through Developmental Surveillance and Screening. *Pediatrics*. Jan 2020; 145(1). PMID 31843861
114. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. Nov 2021; 23(11): 2029-2037. PMID 34211152
115. Malinowski J, Miller DT, Demmer L, et al. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. *Genet Med*. Jun 2020; 22(6): 986-1004. PMID 32203227
116. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. Nov 2010; 12(11): 742-5. PMID 20962661
117. Manning M, Hudgins L. Addendum: Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. Dec 2020; 22(12): 2126. PMID 32514088
118. Waggoner D, Wain KE, Dubuc AM, et al. Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. Oct 2018; 20(10): 1105-1113. PMID 29915380
119. South ST, Lee C, Lamb AN, et al. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. *Genet Med*. Nov 2013; 15(11): 901-9. PMID 24071793

120. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med.* May 2013; 15(5): 399-407. PMID 23519317
121. Department of Healthcare Services Provider Manual Guideline. TAR and Non-Standard Benefits List: Codes 0001M thru 0999U. Accessed January 15, 2026, from [https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/AFECB45B-D2C9-46AD-93A8-5C614B0E79A5/tarandnoncd0.pdf?access\\_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO](https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/AFECB45B-D2C9-46AD-93A8-5C614B0E79A5/tarandnoncd0.pdf?access_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO)
122. Department of Healthcare Services Provider Manual Guideline. TAR and Non-Standard Benefits List: Codes 80000 thru 89999. Accessed January 15, 2026, from [https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/30EEEF3C3-9AF6-4388-B324-DEB87CA7CD81/tarandnoncd8.pdf?access\\_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO](https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/30EEEF3C3-9AF6-4388-B324-DEB87CA7CD81/tarandnoncd8.pdf?access_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO)
123. Department of Healthcare Services Provider Manual Guideline. TAR and Non-Standard Benefits List: Codes R0000 thru S9999. Accessed January 15, 2026, from [https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/AEC3E0B3-3571-4BD7-AF5F-4C43589616BA/tarandnoncds.pdf?access\\_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO](https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/AEC3E0B3-3571-4BD7-AF5F-4C43589616BA/tarandnoncds.pdf?access_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO)
124. Department of Healthcare Services Provider Manual Guideline. Pathology: Molecular Pathology. Accessed January 15, 2026, from [https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/D56B6486-27C2-40E5-ACDF-E5E4AA599CA5/pathmolec.pdf?access\\_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO](https://mcweb.apps.prd.cammis.medi-cal.ca.gov/assets/D56B6486-27C2-40E5-ACDF-E5E4AA599CA5/pathmolec.pdf?access_token=6UyVkRRfByXTZEWIh8j8QaYyIPyP5ULO)

**Documentation for Clinical Review**

Please provide the following documentation:

- History and physical and/or consultation notes including:
  - Clinical findings (i.e., pertinent symptoms and duration)
  - Birth records (if applicable)
  - Diagnosis
  - Treatment plan (if applicable)
- Genetic counseling notes (if applicable)
- Specific test(s) requested
- Radiology report(s) and interpretation (i.e., MRI, CT, PET)
- Other pertinent multidisciplinary notes/reports: (i.e., psychological or psychiatric evaluation, physical therapy, multidisciplinary pain management), when applicable

Post Service (in addition to the above, please include the following):

- Laboratory report(s)

**Coding**

*The list of codes in this Medical Policy is intended as a general reference and may not cover all codes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy.*

| Type | Code  | Description   |
|------|-------|---|
| CPT® | 0156U | Copy number (e.g., intellectual disability, dysmorphology), sequence analysis<br><i>(Includes SMASH™, New York Genome Center, Marvel Genomics™)</i>   |
|      | 0170U | Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis<br><i>(Includes Clarifi™, Quadrant Biosciences, Inc)</i> |

| Type  | Code  | Description  |
|-------|-------|--|
|       | 0209U | Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities<br><i>(Includes CNGnome™, PerkinElmer Genomics)</i>  |
|       | 81228 | Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [CGH] microarray analysis  |
|       | 81229 | Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis                                       |
|       | 81349 | Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis  |
|       | 81470 | X-linked intellectual disability (XLID) (e.g., syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, LICAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2  |
|       | 81471 | X-linked intellectual disability (XLID) (e.g., syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, LICAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2 |
| HCPCS | S3870 | Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability  |

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

| Effective Date | Action   |
|----------------|--|
| 03/01/2026     | New policy.  |
| 06/01/2026     | Administrative update. Definitions of Decision Determinations section updated. |

**Definitions of Decision Determinations**

**Healthcare Services:** For the purpose of this Medical Policy, Healthcare Services means procedures, treatments, supplies, devices, and equipment.

**Medically Necessary or Medical Necessity** means reasonable and necessary services to protect life, to prevent significant illness or significant disability, or alleviate severe pain through the diagnosis or treatment of disease, illness, or injury, as required under W&I section 14059.5(a) and 22 CCR section 51303(a). Medically Necessary services must include services necessary to achieve age-appropriate growth and development, and attain, maintain, or regain functional capacity.

For Members less than 21 years of age, a service is Medically Necessary if it meets the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) standard of Medical Necessity set forth in 42

USC section 1396d(r)(5), as required by W&I sections 14059.5(b) and 14132(v). Without limitation, Medically Necessary services for Members less than 21 years of age include all services necessary to achieve or maintain age-appropriate growth and development, attain, regain or maintain functional capacity, or improve, support, or maintain the Member's current health condition. Contractor must determine Medical Necessity on a case-by-case basis, taking into account the individual needs of the Child.

### Criteria Determining Experimental/Investigational Status

Below is an excerpt of the language taken from California Children's Services Numbered Letter 05-1020.\*

\*Department of Healthcare Services Numbered Letter 05-1020. Accessed April 21, 2026, from <https://www.dhcs.ca.gov/services/ccs/Documents/CCS-NL-05-1020-Experimental-and-Investigational-Services.pdf>

### Policy

- A. The California Children's Services (CCS) Program and the Genetically Handicapped Persons Program (GHPP) will not provide coverage for experimental services unless specifically authorized by law.
- B. The CCS Program and GHPP may provide coverage for an investigational service if:
  1. It is approved by the FDA under any Investigational New Drug (IND) Application; or
  2. It is authorized for use under the State of California's Right to Try Act; and
  3. Its use is consistent with its FDA-approved IND Application or the State of California's Right to Try Act;
- C. Additional criteria that will be considered in the adjudication process include:
  1. Conventional therapy will not adequately treat the intended patient's condition;
  2. Conventional therapy will not prevent progressive disability or premature death;
  3. The provider of the proposed service has a record of safety and success with it or equivalent to that of other providers of the investigational services;
  4. Other criteria (e.g., cost and availability) may be considered in the adjudication of a given request in cases in which more than one investigational service is available;
  5. There is reasonable expectation that the investigational service will significantly prolong the patient's life or will maintain or restore a range of physical and social function suited to activities of daily living; and
  6. The service is not being performed as part of a research study protocol. For a beneficiary with cancer who participates in a clinical trial for cancer, California Health and Safety Code (HSC) §1370.6 requires that all routine patient care costs related to the clinical trial be covered if the beneficiary's CCS-paneled treating physician recommends participation in the clinical trial after determining that participation in the clinical trial has a meaningful potential to benefit the enrollee. The coverage does not include investigational services that have not been approved by the FDA and that are associated with the clinical trial.

### Feedback

Blue Shield of California Promise Health Plan is interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration. Our medical policies are available to view or download at [www.blueshieldca.com/en/bsp/providers](http://www.blueshieldca.com/en/bsp/providers).

For medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

Questions regarding the applicability of this policy should be directed to the Blue Shield of California Promise Health Plan Prior Authorization Department at (800) 468-9935, or the Complex Case Management Department at (855) 699-5557 (TTY 711) for San Diego County and (800) 605-2556 (TTY 711) for Los Angeles County or visit the provider portal at [www.blueshieldca.com/en/bsp/providers](http://www.blueshieldca.com/en/bsp/providers).

*Disclaimer: Blue Shield of California Promise Health Plan may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as member health services contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member health services contracts may differ in their benefits. Blue Shield of California Promise Health Plan reserves the right to review and update policies as appropriate.*